<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39426493</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Determination of T cell response against XBB variants in adults who received either monovalent wild type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster.</ArticleTitle><Pagination><StartPage>107271</StartPage><MedlinePgn>107271</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2024.107271</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(24)00342-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">As the SARS-CoV-2 virus evolves more rapidly than vaccines are updated, T cell immunity potentially confers protection against disease progression and death from new variants. In this study, we aimed to assess whether the current boosting vaccination schemes offer sufficient T cell protection against new SARS-CoV-2 variants.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">. 292 adults who had received the second booster of either monovalent wild type vaccines (inactivated virus or mRNA) (cohort 1) or the second/third booster of bivalent WT/BA.4-5 mRNA vaccine (cohort 2) were recruited in Hong Kong. All participants showed no serological evidence of recent infection of SARS-CoV-2. Blood samples of each participant were collected before and one-month after receiving the booster. T cell and antibody responses were determined by flow cytometry and neutralization test respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">. Among all vaccination strategies, only the adults who had received the bivalent vaccine as the third booster dose significantly elicited T cell responses to the XBB variant. Either monovalent or bivalent mRNA but not inactivated virus vaccine as the second/third booster induced antibody against different XBB variants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">. Receiving bivalent mRNA vaccine as the third booster is preferrable to induce both T cell and antibody responses against XBB.</AbstractText><CopyrightInformation>Copyright Â© 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yun Sang</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China.; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Chee Wah</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore.; Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Ka Chun</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China.; Centre for Health Systems and Policy Research, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chunke</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China.; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yuanxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China.; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yiu</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine &amp; Therapeutics, Faculty of Medicine, The Chinese University of Hong, Kong, Hong Kong SAR, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Kwun Cheung</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Medicine &amp; Therapeutics, Faculty of Medicine, The Chinese University of Hong, Kong, Hong Kong SAR, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Ken Kp</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China.; Department of Medicine &amp; Therapeutics, Faculty of Medicine, The Chinese University of Hong, Kong, Hong Kong SAR, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peiris</LastName><ForeName>Malik</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Centre for Immunology and Infection, Hong Kong Science Park, Shatin, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Chris Ka Pun</ForeName><Initials>CKP</Initials><AffiliationInfo><Affiliation>The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China.; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China.; SH Ho Research Centre for Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.; School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR. Electronic address: kapunmok@cuhk.edu.hk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Medicine &amp; Therapeutics, Faculty of Medicine, The Chinese University of Hong, Kong, Hong Kong SAR, PR China.; SH Ho Research Centre for Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.. Electronic address: dschui@cuhk.edu.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cross-reactive</Keyword><Keyword MajorTopicYN="N">T cell response</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">XBB</Keyword><Keyword MajorTopicYN="N">bivalent vaccine</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>20</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>19</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39426493</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2024.107271</ArticleId><ArticleId IdType="pii">S1201-9712(24)00342-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle>